Egrifta (Tesamorelin) Pediatric Safety: What Parents and Clinicians Need to Know About Use in Children Under 12

What Is Tesamorelin and Why Does Pediatric Safety Matter?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) approved by the FDA in 2010 for reducing excess abdominal fat in HIV-infected adults with lipodystrophy [1]. The drug works by binding to GHRH receptors in the anterior pituitary gland, triggering pulsatile release of endogenous growth hormone (GH). In adults with HIV-associated lipodystrophy, the key trial by Falutz et al. Demonstrated a 15% reduction in visceral adipose tissue (VAT) over 26 weeks compared to placebo [2].

Pediatric safety matters here because HIV-associated lipodystrophy can also affect children receiving antiretroviral therapy (ART). Prevalence estimates of lipodystrophy in HIV-infected children on ART range from 1% to 33% depending on the definition and cohort studied, according to a systematic review published in Pediatric Infectious Disease Journal [3]. Some clinicians have considered tesamorelin as a potential intervention for these children. The problem is straightforward: no controlled data exist.

The FDA label for Egrifta SV explicitly states that "safety and effectiveness in pediatric patients have not been established" [4]. This is not a soft disclaimer. It reflects a genuine absence of evidence. The developing endocrine system in children under 12 responds to GH-axis stimulation differently than the adult system, and the risks of intervening in that axis without pediatric-specific data are clinically meaningful.

How Tesamorelin Works and Why the Mechanism Raises Pediatric Concerns

Tesamorelin binds to pituitary GHRH receptors and stimulates release of stored GH in a pulsatile pattern that partially mimics physiologic secretion [5]. In adults, this produces measurable increases in serum IGF-1 (insulin-like growth factor 1) and corresponding reductions in visceral fat. The adult GH axis is relatively stable. The pediatric GH axis is not.

Children under 12 are in active phases of linear growth, bone maturation, and metabolic programming. GH secretion in this age group is already elevated compared to adults, with peak secretion occurring during puberty. Introducing an exogenous GHRH analog into this system creates several specific concerns.

First, supraphysiologic IGF-1 levels. The Endocrine Society's 2011 clinical practice guidelines on GH use note that sustained IGF-1 elevation above the age-adjusted normal range is associated with increased risk of certain malignancies in observational studies [6]. Children have higher baseline IGF-1 trajectories, so the additive effect of tesamorelin on top of normal developmental secretion is unpredictable without dedicated pharmacokinetic studies.

Second, altered bone maturation. GH accelerates epiphyseal plate activity. In children with open growth plates, uncontrolled GH stimulation could theoretically advance bone age disproportionately to chronological age, potentially compromising final adult height. This is a well-documented concern with exogenous GH therapy, which is why pediatric GH treatment requires regular bone-age monitoring via hand/wrist radiographs [7].

Third, glucose dysregulation. Tesamorelin's adult trials showed fasting glucose increases in treated patients. The Phase 3 trial reported that HbA1c increased by 0.12% in the tesamorelin group versus 0.02% in placebo [2]. Children with HIV are already at elevated metabolic risk from both the virus and antiretroviral therapy. Adding a glucose-raising agent to this population without dose-finding studies in children creates an unquantified risk.

What the FDA Label Says About Pediatric Use

The prescribing information for Egrifta SV is unambiguous. Section 8.4 (Pediatric Use) states: "Safety and effectiveness of EGRIFTA SV in pediatric patients have not been established" [4]. No pediatric studies were required as a condition of approval, and Theratechnologies has not publicly registered any pediatric trials for tesamorelin on ClinicalTrials.gov as of May 2026.

This labeling status means tesamorelin falls into the category of drugs with no pediatric exclusivity data. Under the Pediatric Research Equity Act (PREA), the FDA can require manufacturers to conduct pediatric studies for drugs likely to be used in children. The FDA did not invoke PREA for tesamorelin, likely because HIV-associated lipodystrophy in children under 12 was not considered a sufficiently common indication to justify mandatory studies at the time of approval [8].

The absence of a PREA requirement does not mean the drug is safe in children. It means the FDA determined that the adult indication did not warrant forced pediatric investigation. Any use in children under 12 is therefore off-label, unsupported by regulatory evidence, and carries full liability for the prescribing clinician.

What Adult Clinical Trials Tell Us (and What They Cannot)

The two key Phase 3 trials of tesamorelin enrolled exclusively adult patients aged 18 to 65 with confirmed HIV infection and excess visceral adiposity. In the primary efficacy study (N=816), tesamorelin 2 mg daily reduced trunk fat by 15.2% versus 5.2% growth in the placebo group at 26 weeks [2]. The extension study showed that VAT reaccumulated within 3 months of discontinuation, indicating the effect is not durable [9].

Common adverse events in adult trials included injection site reactions (erythema, pruritus, pain) in approximately 24% of patients, arthralgia (13.3%), peripheral edema (6.1%), and myalgia (5.5%) [4]. Fluid retention-related effects are particularly relevant to pediatric extrapolation because children have different body water compartment ratios and may be more susceptible to edema-related complications.

The adult trials excluded patients with active malignancy, and the label carries a warning about the theoretical risk of GH-stimulated tumor growth. The FDA's post-marketing surveillance data (FAERS database) have not identified a clear malignancy signal in adults, but the monitoring period and exposed population are insufficient to rule out long-term risk in a growing child whose cells are naturally in a higher proliferative state [10].

Extrapolating adult pharmacokinetic data to children is unreliable for peptide hormones. Children under 12 have different volumes of distribution, renal clearance rates, and receptor density profiles. Without pediatric PK/PD modeling, no safe dose can be estimated.

Growth Hormone Axis Considerations Specific to Children Under 12

The hypothalamic-pituitary-GH axis in children under 12 is functionally different from the adult axis in at least three measurable ways.

GH secretion is pulsatile in all ages, but pulse amplitude and frequency are higher in prepubertal children. Data from serial GH sampling studies show that children aged 5 to 10 secrete approximately 0.5 to 0.7 mg of GH per day, compared to 0.1 to 0.3 mg/day in healthy adults [11]. Adding a GHRH analog to an already-active secretory pattern could produce GH peaks that exceed the physiologic range by an unpredictable margin.

IGF-1 reference ranges are age-dependent and rise sharply during childhood. The Mayo Clinic reference laboratory defines the upper normal IGF-1 for a 7-year-old as approximately 280 ng/mL, while the adult upper limit is roughly 270 ng/mL for a 30-year-old [12]. A drug that raises IGF-1 by 30 to 50% in adults (as tesamorelin does) could push a child's IGF-1 well into the supraphysiologic range, beyond what occurs even during normal pubertal growth spurts.

Cortisol suppression is another concern. GHRH and cortisol-releasing hormone (CRH) share regulatory overlap at the hypothalamic level. Studies in adults have shown that tesamorelin does not significantly alter the cortisol axis [5], but the developing hypothalamic-pituitary-adrenal (HPA) axis in children is more sensitive to perturbation. Pediatric endocrinologists routinely monitor adrenal function in children receiving exogenous GH, and the same caution would apply to GHRH analogs [13].

HIV-Associated Lipodystrophy in Children: Alternative Management Approaches

Lipodystrophy in children with HIV is real and clinically significant. It affects body image, medication adherence, and metabolic health. The question is not whether it needs treatment but whether tesamorelin is the right treatment for a child under 12.

Current pediatric guidelines from the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV recommend lifestyle intervention as first-line management for ART-associated metabolic complications, including lipodystrophy [14]. This includes structured exercise programs, dietary modification with reduced refined carbohydrates, and optimizing the ART regimen to avoid drugs most associated with fat redistribution.

Switching ART is the most evidence-supported pharmacologic strategy. Stavudine (d4T) and zidovudine (AZT), the thymidine analogs most strongly linked to lipoatrophy, are no longer recommended as first-line therapy. Studies in the PENPACT-1 trial (N=263 children) showed that switching from thymidine analogs to tenofovir or abacavir-based regimens led to partial reversal of subcutaneous fat loss over 48 weeks [15].

Metformin has limited pediatric data for HIV-associated insulin resistance and visceral adiposity. A small randomized trial in HIV-infected adolescents (N=31, ages 12 to 19) showed modest reductions in waist circumference with metformin 500 mg twice daily [16]. This trial only included adolescents, not children under 12, but the drug has broader pediatric safety data from the type 2 diabetes context.

Recombinant human growth hormone (rhGH) has been studied in HIV-associated lipodystrophy in adults but not in children for this indication. RhGH does have extensive pediatric safety data for other indications (GH deficiency, Turner syndrome, idiopathic short stature), which makes its risk profile in children better characterized than tesamorelin's. The Pediatric Endocrine Society maintains monitoring guidelines for children on rhGH that include quarterly IGF-1 levels, annual bone age radiographs, and glucose monitoring [7].

What Would Be Needed Before Pediatric Use Could Be Justified

Moving tesamorelin toward any legitimate pediatric application would require a structured development program. The minimum evidentiary standard would include several components.

A pediatric pharmacokinetic study in at least two age cohorts (2 to 6 years and 7 to 11 years) with dense PK sampling would be required to establish dose-exposure relationships. The FDA's 2014 guidance on pediatric study design recommends population PK modeling with allometric scaling as a starting point for peptide drugs [17].

A dose-finding safety study with at least 6 months of follow-up would be needed to assess IGF-1 trajectories, bone age progression, glucose metabolism, and injection-site tolerability. Given the small target population, this would likely require a multi-center international design.

Long-term safety monitoring for at least 2 years post-treatment would be necessary to evaluate effects on linear growth velocity, pubertal timing, and any signal for neoplasia. The ICH E11 guideline on pediatric drug development specifies that drugs affecting growth should include pre-specified growth monitoring endpoints [18].

No such studies are currently registered, planned, or funded. This means tesamorelin pediatric use remains in the field of theoretical discussion, not clinical practice.

Monitoring Recommendations If Off-Label Use Occurs

In rare circumstances, a pediatric endocrinologist or HIV specialist may consider off-label tesamorelin in a child under 12 when all standard alternatives have failed and visceral adiposity poses immediate metabolic danger. This should happen only within an institutional review framework or with documented informed consent that explicitly addresses the absence of pediatric data.

If off-label use proceeds, the following monitoring protocol would be the minimum standard of care based on extrapolation from pediatric GH treatment guidelines [7] and tesamorelin's adult safety profile [4].

Baseline assessments before initiating therapy should include: IGF-1 and IGFBP-3 levels, fasting glucose and HbA1c, lipid panel, bone age radiograph (left hand/wrist), height velocity over the preceding 6 to 12 months, liver function tests, and a complete body composition assessment (DEXA preferred).

During treatment, IGF-1 should be measured every 4 to 6 weeks initially, then quarterly if stable. Glucose monitoring (fasting glucose at minimum, HbA1c every 3 months) is non-negotiable given the adult signal. Bone age should be repeated every 6 months. Height should be measured using a stadiometer at every visit, with growth velocity calculated at 6-month intervals. Any acceleration of bone age relative to chronological age, any IGF-1 value exceeding +2 SD for age, or any fasting glucose above 100 mg/dL should trigger immediate reassessment.

Discontinuation criteria should be pre-specified. Treatment should stop if bone age advances more than 1 year beyond chronological age over a 6-month period, if IGF-1 remains persistently above the age-adjusted upper limit of normal despite dose reduction, or if the child develops impaired fasting glucose (100 to 125 mg/dL) or diabetes (fasting glucose ≥126 mg/dL on two occasions) [19].

Regulatory and Legal Considerations for Prescribers

Prescribing tesamorelin to a child under 12 carries specific regulatory and medicolegal implications. Off-label prescribing is legal in the United States when based on clinical judgment, but the prescriber assumes full responsibility for the treatment decision.

The American Academy of Pediatrics (AAP) has stated that off-label drug use in children is sometimes necessary but should be accompanied by thorough documentation of the rationale, a discussion with the family about the lack of pediatric data, and enhanced monitoring [20]. Institutional pharmacy and therapeutics (P&T) committees may require prior approval for off-label use of drugs with no pediatric precedent.

From a liability perspective, prescribing a drug with no pediatric efficacy data, no pediatric PK data, and a mechanism of action that raises specific developmental concerns places the clinician in a difficult position if an adverse outcome occurs. Documentation should include the specific clinical justification, the alternatives that were tried and failed, the informed consent discussion, and the monitoring plan.

Insurance coverage is another practical barrier. Payers rarely cover off-label pediatric use of drugs approved only for adults with HIV-associated lipodystrophy. The average wholesale price of Egrifta SV is approximately $4,200 per month [21], making self-pay untenable for most families.

The Bottom Line for Clinicians and Families

Tesamorelin has a defined role in adult HIV-associated lipodystrophy with solid Phase 3 evidence supporting its efficacy for visceral fat reduction. That evidence does not extend to children under 12 in any form. No pharmacokinetic studies, no dose-finding studies, no safety studies, and no efficacy studies exist in this population. The drug's mechanism of stimulating the GH axis creates biologically plausible risks that are specific to growing children, including unpredictable IGF-1 elevation, accelerated bone maturation, and glucose dysregulation.

Clinicians managing HIV-associated lipodystrophy in children should prioritize ART regimen optimization, lifestyle interventions, and, where metabolic risk is severe, consider agents with broader pediatric safety databases. Tesamorelin should not be prescribed to children under 12 outside of a formal research protocol or an extensively documented, specialist-supervised, last-resort clinical scenario with pre-specified monitoring and stopping rules.